Glutamine and Intestinal Protein Metabolism
Overview
Gut barrier plays a major role in defence of the organism. During catabolic states, like major surgery or inflammation, gut barrier could be altered. It has been reported that preoperative nutritional support may have beneficial effects on clinical outcome in patients with surgery on gastrointestinal tract. Glutamine, which is a conditionally essential amino, have been reported to modulate inflammatory, antioxidant responses and protein metabolism in intestine. In addition, glutamine supply improves clinical outcome in critically ill patients. Antioxidant micronutrients may also have some beneficial effects in intestine by improving antioxidant response and might also regulate protein expression. Nevertheless, effects of glutamine combined to antioxidant micronutrients have not been evaluated. Thus, the aim of this study will be to assess the influence of glutamine and glutamine-antioxidant micronutrients-containing solutions on intestinal response in humans.
Full Title of Study: “Comparative Effects of Glutamine and Glucose on Intestinal Protein Metabolism in Healthy Humans”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Randomized
- Intervention Model: Crossover Assignment
- Primary Purpose: Treatment
- Masking: None (Open Label)
Interventions
- Drug: Glutamine
- Drug: Glucose
- Drug: glutamine-antioxidants containing solution
Clinical Trial Outcome Measures
Primary Measures
- Impact on protein synthesis rate and proteolytic activities in intestine.
- Time Frame: at the end of infusion (hour 5)
Secondary Measures
- Comparison of protein expression pattern and glutathione synthesis.
- Time Frame: at the end of infusion (hour 5)
Participating in This Clinical Trial
Inclusion Criteria
- Healthy volunteers, male and female, aged between 18 and 50 years, negatives for HIV1, 2 and for HVC and HVB – BMI between 20 and 24 kg/m², – giving their written informed consent – no-smokers – no allergic and digestive antecedents Exclusion Criteria:
- smokers – Allergic and digestive antecedents, – pregnancy
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 50 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- University Hospital, Rouen
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Pierre Déchelotte, MD, PhD, Principal Investigator, University Hospital, Rouen
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.